Equities

National Research Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert

National Research Corp

Actions
  • Price (EUR)10.30
  • Today's Change-0.90 / -8.04%
  • Shares traded200.00
  • 1 Year change-36.02%
  • Beta0.5717
Data delayed at least 15 minutes, as of Feb 13 2026 07:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

National Research Corporation, doing business as NRC Health, is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations in the United States. Its digital solutions consist of four solution categories: Patient Experience, Consumer Experience, Employee Experience, and Market Experience, which can be implemented both collectively as an enterprise solution or individually to meet specific needs within the organization. Its Marketing solutions are subscription-based services that allow for improved tracking of awareness, perception, and consistency of healthcare brands; real-time assessment of competitive differentiators, and enhanced segmentation tools. Its Reputation solutions allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs better consumer decision-making.

  • Revenue in USD (TTM)137.39m
  • Net income in USD11.60m
  • Incorporated2021
  • Employees368.00
  • Location
    National Research Corp1245 Q StreetLINCOLN 68508United StatesUSA
  • Phone+1 (402) 475-2525
  • Fax+1 (302) 655-5049
  • Websitehttps://nrchealth.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.